Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00515502 |
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK573719 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for COPD.
Condition | Intervention | Phase |
---|---|---|
Chronic Obstructive Pulmonary Disease (COPD) |
Drug: GSK573719 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Crossover Assignment, Safety Study |
Official Title: | See Detailed Description |
Enrollment: | 24 |
Study Start Date: | June 2007 |
Study Completion Date: | November 2007 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 (3 escalating mcg doses will be used) and tiotropium bromide (18µg) via DPI in COPD patients
Ages Eligible for Study: | 40 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Respiratory criteria
Cardiovascular criteria
Concurrent medication criteria
Germany | |
GSK Investigational Site | |
Hamburg, Germany, 22291 | |
GSK Investigational Site | |
Berlin, Germany, 14050 | |
Germany, Niedersachsen | |
GSK Investigational Site | |
Hannover, Niedersachsen, Germany, 30625 |
Study Director: | GSK Clinical Trials, MD, MSc, FFPM | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | AC4108123 |
Study First Received: | August 9, 2007 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00515502 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
GSK573719, chronic obstructive pulmonary disease, muscarinic receptor antagonist |
Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Respiration Disorders Tiotropium Pulmonary Disease, Chronic Obstructive |